FDA mandates new labels for anti-fungals

June 1, 2001

Miami - The FDA last month issued a health warning concerning two popular anti-fungal drugs used to treat onychomycosis, requiring that labels for Sporanox (Janssen Pharmaceuticals) and Lamisil (Novartis) carry stronger warnings about potential liver damage. Sporanox also must warn against potential heart disease, the administration said.